InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,709.54
(
0.01%
)
US TECH 100
19,320.04
(
0.36%
)
Dow Jones
42,196.52
(
0.09%
)
Brent Oil
74.61
(
-0.01%
)
Bitcoin
61,021.13
(
0.66%
)
Post# of 253268
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: ghmm post# 87479

Tuesday, 12/15/2009 9:12:35 AM

Tuesday, December 15, 2009 9:12:35 AM

Post# of 253268
SGEN gets $60M upfront and retains full commercialization rights for SGN-35 in the US and Canada. Milestone payments to Seattle Genetics could reach $230M. Takeda will fund worldwide development costs on a 50:50 basis and all of the Japan development costs.

Seattle Genetics sells non-U.S. drug rights to Takeda

http://www.reuters.com/article/idCNTOE5BE07A20091215?rpc=44
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up